Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.18 USD | -4.95% | -71.24% | -72.30% |
04-30 | Canaccord Genuity Cuts Price Target on Annovis Bio to $26 From $36, Maintains Buy Rating | MT |
04-29 | Sector Update: Health Care Stocks Edge Higher Late Afternoon | MT |
Business Summary
Number of employees: 11
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 73 | 30/04/08 | |
Melissa Gaines
CTO | Chief Tech/Sci/R&D Officer | - | - |
Cheng Fang
CTO | Chief Tech/Sci/R&D Officer | - | 17/05/21 |
Andrew Walsh
PRN | Corporate Officer/Principal | - | 11-30 |
Eve M. Damiano
LAW | General Counsel | - | 31/12/21 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Hoffman
CHM | Chairman | 73 | 31/12/13 |
Chief Executive Officer | 73 | 30/04/08 | |
Reid McCarthy
BRD | Director/Board Member | 70 | 08/04/21 |
Claudine Bruck
BRD | Director/Board Member | 68 | 31/12/14 |
Mark White
BRD | Director/Board Member | 68 | 31/12/15 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 11,011,299 | 8,303,262 ( 75.41 %) | 0 | 75.41 % |
Company contact information
Annovis Bio, Inc.
101 Lindenwood Drive Suite 225
19355, Malvern
+(484) 875-3192
http://www.annovisbio.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-72.30% | 57.04M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+6.79% | 14.16B | |
+38.61% | 12.63B |
- Stock Market
- Equities
- ANVS Stock
- Company Annovis Bio, Inc.